Month: July 2025

Introduction and Objective: Adipose tissue (AT) immunoregulatory T cells (Tregs) are major determinants of systemic metabolism. In the lean phenotype, Tregs protect against inflammation and maintain homeostasis in AT. However, their abundance profoundly decreases in obesity, leading to inflammation, insulin resistance, and other inflammation-driven comorbidities. The transcription factor forkhead box protein P3 (Foxp3) is essential […]

Introduction and Objective: Guidelines endorse CGM use during hospitalizations with proper support. However, barriers and facilitators for optimal implementation in the pediatric hospital setting are unknown. We aimed to evaluate user experiences before and after implementing a pediatric hospital CGM policy.Methods: In September 2024, we implemented a hospital policy to support using personal CGM to […]

Introduction and Objective: AI-driven glucose predictions help CGM users manage glucose levels more proactively. The Accu-Chek® SmartGuide Predict app notifies of low glucose levels within 30 minutes (LGP), nighttime hypoglycemia risk (NLP), and provides a continuous 2-hour glucose forecast (GP). This study evaluates the potential glycemic benefits of the app via in-silico analysis.Methods: Using UVa’s […]

Introduction and Objective: Gestational diabetes mellitus (GDM) risk varies by area and is potentially associated with social disparity and variation in the built environment. There remains limited evidence examining the association between socio-ecological factors and GDM risk. This study examined the association between socio-ecological factors and GDM risk at local area level over time in […]

Introduction and Objective: SGLT-2 inhibitors (SGLT-2i) reduce heart failure (HF) hospitalization among HF patients and slow kidney disease progression and lower cardiovascular risk among patients with chronic kidney disease (CKD). We estimated the proportion of patients with type 2 diabetes and either HF or CKD with an active prescription for an SGLT2i and identified factors […]

Introduction and Objective: Clinical trials were not powered to examine if the cardiovascular (CV) benefits of empagliflozin (EMPA) in patients with type 2 diabetes (T2D) are consistent across demographic factors.Methods: Using Medicare data (2014-2020), we compared 1:1 propensity score-matched patients aged ≥65 years with T2D initiating EMPA vs DPP4i for MACE, hospitalization for heart failure […]

Introduction and Objective: SGLT2i have major cardiorenal benefits for people with type 2 diabetes. While some guidelines recommend temporarily withholding SGLT2i during hospitalization, limited evidence suggests many people may not restart SGLT2i following discharge. We examined if hospitalization was a risk factor for SGLT2i discontinuation, and if this differed to other diabetes therapy (DPP-4i) not […]

Introduction and Objective: Diabetes device use in T1D is associated with improved clinical outcomes. However, many people experience device-related skin reactions. Our aim was to assess psychosocial outcomes between YYA with T1D that experience device-related skin reactions and those that do not.Methods: YYA (2-25 years) with T1D that use diabetes devices completed an in-house developed […]

Introduction and Objective: Transgender, non-binary, and genderqueer people experience systematic barriers in receipt of medical care. Our objective was to understand patterns of diabetes treatment/outcomes for this population.Methods: Patients with an ICD code diagnosis of T2DM between 01/01/2021 and 01/13/2024 in nationwide Epic EHR data were included and A1c control, receipt of antidiabetic medication classes, […]

Introduction and Objective: The REGENT-1 trial evaluated the Re-Cellularization via Electroporation Therapy (ReCET™) System, which uses pulsed electric fields (PEF) to regenerate duodenal mucosa and submucosa. We examined the effect of ReCET™ across energy dose cohorts on CGM metrics.Methods: REGENT-1studied endoscopic PEF therapy at three doses in T2D adults on 1-4 non-insulin agents. Group 1) […]